Mapping of Phospholipase A2 Receptor Epitopes in Idiopathic Membranous Nephropathy and Clinical Relevance of Epitope Profiles
Journal of the American Society of Nephrology · 2025
DOI: 10.1681/asn.0000000962 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society of Nephrology, 2025. Verfasst von Yanan Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Receptors, Phospholipase A2, Epitopes, Epitope Mapping. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: High-level Hospital Construction Project of Guangdong Provincial People's Hospital, National Natural Science Foundation of China.
Abstract (Originalsprache)
Key Points Based on the yeast surface display system, we identified three new antigen epitopes of CTLD4, CTLD5, and CTLD6 of phospholipase A2 receptor in membranous nephropathy. In the cohort, 82% of patients showed epitopes beyond Ricin and 56% higher risk for nephrotic syndrome per one more epitope (odds ratio, 1.56; 95% confidence interval, 1.28 to 1.91). Each additional epitope was associated with 15% lower likelihood in clinical remission in this membranous nephropathy cohort (hazard ratio, 0.85; 95% confidence interval, 0.75 to 0.96).
Background
The M-type phospholipase A2 receptor (PLA2R) is the main target antigen of idiopathic membranous nephropathy. Four autoantibody-targeted PLA2R epitope domains, including Ricin, CTLD1, CTLD7, and CTLD8, have been identified. Nevertheless, whether the epitope profile is involved in the progression of PLA2R-associated membranous nephropathy remains controversial. Conventional epitope detection techniques have limitations, and new methods are needed.
Methods
We constructed a yeast surface–displayed PLA2R antigen library by randomly fragmenting the full-length PLA2R gene and expressing them on the yeast surfaces. Fluorescence-activated cell sorting was performed with sera from PLA2R-related membranous nephropathy patients. Antigenic epitopes were identified through sequencing and clustering. To analyze large-scale samples in batches, we used representative monoclonal yeasts of each structural domain, obtained through the sorting procedure for flow analysis. Clinical and laboratory data were collected at baseline and follow-up. Associations between epitope numbers and disease conditions and prognosis were analyzed.
Results
The capacity, diversity, and screening specificity of the PLA2R yeast surface display library were validated. Beyond the reported epitopes, CTLD4, CTLD5, and CTLD6 were newly identified as antigenic targets. In our cohort of 389 idiopathic membranous nephropathy patients, 320 (82%) patients showed epitopes beyond the Ricin domain. The positive rates of CTLD1, CTLD5, and CTLD7 were 53%, 45%, and 54%, respectively, while the detection rates of CTLD6, CTLD8, and CTLD4 were lower at 9%, 8%, and 7%, respectively. The multivariable model demonstrated a 56% higher risk for nephrotic syndrome per epitope increment (odds ratio, 1.56; 95% confidence interval, 1.28 to 1.91) after adjustment for gender, age, disease duration, serum creatinine, and anti-PLA2R titer. Multivariable Cox regression demonstrated that each additional epitope was associated with a 15% lower likelihood in clinical remission (hazard ratio, 0.85; 95% confidence interval, 0.75 to 0.96), with subsequent mediation analysis revealing anti-PLA2R titer accounted for 12% of this effect.
Conclusions
Based on the PLA2R yeast surface display system, we identified three new antigen epitopes of PLA2R in membranous nephropathy. The epitope profiles of PLA2R were associated with disease severity and prognosis of membranous nephropathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
- Department of Internal Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
- Comprehensive AIDS Research Center, Pandemic Research Alliance Unit, Center for Infection Biology, School of Basic Medical Sciences, Tsinghua University, Beijing, China.
- Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.
ORCID-Profile: Yanan Liu, Gang Chen, Junxian Hong, Yangzhong Zhou, Ke Zheng, Zhiying Gao, Peng Xia, Haoyuan Cui, Ruoke Wang, Xuanling Shi, Xuewang Li, Yan Qin
Förderung
- High-level Hospital Construction Project of Guangdong Provincial People's Hospital
- National Natural Science Foundation of China
Zitieren
APA
Liu, Y., Chen, P., Chen, G., Hong, J., Zhou, Y., Zheng, K., Ai, S., Gao, Z., Xia, P., Cui, H., Wang, R., Shi, X., Li, X., Li, X., Zhang, L., & Qin, Y. (2025). Mapping of Phospholipase A2 Receptor Epitopes in Idiopathic Membranous Nephropathy and Clinical Relevance of Epitope Profiles. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.0000000962
Vancouver
Liu Y, Chen P, Chen G, Hong J, Zhou Y, Zheng K, et al. Mapping of Phospholipase A2 Receptor Epitopes in Idiopathic Membranous Nephropathy and Clinical Relevance of Epitope Profiles. Journal of the American Society of Nephrology. 2025. doi:10.1681/asn.0000000962
BibTeX
@article{Liu2025,
author = {Liu, Yanan and Chen, Peng and Chen, Gang and Hong, Junxian and Zhou, Yangzhong and Zheng, Ke and Ai, Sanxi and Gao, Zhiying and Xia, Peng and Cui, Haoyuan and Wang, Ruoke and Shi, Xuanling and Li, Xuemei and Li, Xuewang and Zhang, Linqi and Qin, Yan},
title = {Mapping of Phospholipase A2 Receptor Epitopes in Idiopathic Membranous Nephropathy and Clinical Relevance of Epitope Profiles},
journal = {Journal of the American Society of Nephrology},
year = {2025},
doi = {10.1681/asn.0000000962}
}
EUVIMED